The global nicotine gum market size is expected to reach USD 2.0 billion by 2030, registering a CAGR of 5.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market expansion is anticipated to be fueled by the increasing awareness of the health risks associated with smoking and the increasing availability and acceptance of nicotine replacement therapy. In addition, over the coming years, increased consumer awareness of the importance of nicotine replacement therapies is anticipated to drive demand.
People are looking towards nicotine replacement therapy (NRT), including nicotine gums, as a way to quit smoking as it has been an effective tool for managing nicotine cravings and reducing withdrawal symptoms. NRT works by providing the body with a small dose of nicotine, which helps to alleviate the physical symptoms of withdrawal that often occur when a person stops smoking.
Additionally, many people are aware of the social stigma associated with smoking and want to quit in order to improve their health and well-being. Quitting smoking can lead to numerous health benefits, including a reduced risk of heart disease, lung cancer, and other health problems.
In recent years, there has been a significant shift in public attitudes toward smoking. Smoking is no longer seen as a socially acceptable habit, and many workplaces and public spaces have implemented smoking bans. As a result, many people are feeling more motivated than ever to quit smoking and are turning to NRT products like nicotine gum to help them achieve their goals.
Request a free sample copy or view the report summary: Nicotine Gum Market Report
The 2mg segment held the largest share of 55.9% in 2022. 2mg nicotine gums are an effective solution for managing nicotine cravings and reducing withdrawal symptoms. They work by providing the body with a small dose of nicotine, which helps to alleviate the physical symptoms of withdrawal that often occur when a person stops smoking
However, the 4mg segment is expected to grow at the fastest CAGR of 6.0% over the forecast period owing to increasing depression and anxiety among the young population which is resulting in an increased number of heavy smokers
The pharmacy segment held a significant share of 38.4% in 2022. Buying nicotine gum from a pharmacy provides a certain level of confidentiality for those who are trying to quit smoking or manage their nicotine cravings and require some input from the pharmacists with regard to the variety of products available and their benefits over others
The online segment is expected to grow at the highest CAGR of 6.9% during the forecast period. Shopping for nicotine gum through online distribution channel allows consumers to easily compare prices, features, and reviews of different products. This helps them make an informed decision about which product to buy, ensuring that they get the best value for their money
North America held the highest market share of 29.9% in 2022. The presence of various leading market players in the region is a major factor contributing to the market growth. Also, a rise in health-conscious consumers due to government initiatives and campaigns promoting healthy lifestyles is further driving the market growth in the region. According to the Centers for Disease Control and Prevention (CDC), the smoking rate in the U.S. is approximately 14% as of 2021, which is a significant decline from the 20.9% reported in 2005
Grand View Research has segmented the global nicotine gum market based on type, distribution channel, and region:
Nicotine Gum Type Outlook (Revenue, USD Million, 2017 - 2030)
2mg
4mg
Nicotine Gum Distribution Channel Outlook (Revenue, USD Million, 2017 - 2030)
Supermarkets/Hypermarkets
Convenience Stores
Pharmacies
Online
Nicotine Gum Regional Outlook(Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
China
India
Japan
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
UAE
South Africa
List of Key Players in the Nicotine Gum Market
Johnson & Johnson
Novartis AG
ITC Limited
Cipla Health Limited
Perrigo Company Plc.
Teva Canada
Philip Morris
British American Tobacco PLC
"The quality of research they have done for us has been excellent..."